The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains slowed down in the second half of 2024. The downside in the second half was due...
Edward M. MD Kaye, the CEO of $STOK ($STOK), sold 6,786 shares of the company on 12-09-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 9.9% of their shares....
Barry Ticho, the CHIEF MEDICAL OFFICER of $STOK ($STOK), sold 13,945 shares of the company on 12-06-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 22.8%...
Stoke Therapeutics, Inc. STOK announced that the FDA has granted a Breakthrough Therapy designation to its investigational candidate, zorevunersen (STK-001), for the treatment of Dravet syndrome, a severe...
Barry Ticho, the CHIEF MEDICAL OFFICER of $STOK ($STOK), sold 10,000 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 16.3%...
Stocks are slightly up this morning as market participants reacted to February's US Durable Goods Report.
This small-cap biotech might be a hidden gem.
The company's shares fell after it released early trial results on its lead therapy.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced...